Subcutaneous Entyvio Wins US FDA Nod for Crohn’s Disease: Takeda

Takeda Pharmaceutical has snared US FDA approval for a label expansion of its Entyvio (vedolizumab) subcutaneous formulation for the maintenance treatment of Crohn’s disease, the company said. The FDA blessing was granted for Entyvio Pen, a single-dose prefilled pen version...read more